Study S000886

A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07803744
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: RECRUITING
Enrollment: 18
Start: 2026-09-11
Primary completion: 2026-12
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 1; Overweight; Obesity
Interventions: DRUG:Tirzepatide; DRUG:Acetaminophen; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:I8F-MC-GPJI

Registered primary outcomes

Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen [Predose on Day 1 through 36 hours post dose]
PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen [Predose on Day 1 through 36 hours post dose]
PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen [Predose on Day 1 through 36 hours post dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.